Skip to main content
Premium Trial:

Request an Annual Quote

Genosity, Olink Proteomics Ink Strategic Collaboration

NEW YORK – Genosity and Olink Proteomics of Sweden on Tuesday announced a strategic services and collaboration agreement for the US.

Under the deal, Genosity will offer Olink's proximity extension assay technology at its CLIA laboratory and will include the technology in its Genosity Integrated Genomics Toolkit software.

The collaboration allows Genosity to add high-throughput proteomics with next-generation sequencing readout to its repertoire of technologies and Uppsala, Sweden-based Olink to expand into the US market for protein biomarker discovery services.

Financial and other terms of the deal were not disclosed.

"The ability to perform such highly multiplexed, proteomic profiling experiments with the same sequencers we use to sequence genomes is revolutionary," Genosity CTO and Cofounder Robert Daber said in a statement.

Olink's immunoassays with NGS readout use pairs of antibodies linked to complementary oligonucleotides, which form a PCR target sequence once the antibodies bind to their target protein. The Olink Explore platform can currently measure up to 1,536 proteins using less than 3 microliters of sample on an Illumina NovaSeq system. 

The deal is the second this month for Woodbridge, New Jersey-based Genosity and the latest in a string of recent partnerships. Last week, the firm signed a comarketing agreement with Personal Genome Diagnostics around PGDx's Elio Tissue Complete cancer profiling assay. In January, Genosity partnered with Columbia University to study the genetics of cardiac amyloidosis.

Olink has already begun partnering with other firms to expand the reach of its assays. In July, for example, it made WuXi NextCode its exclusive assay provider in China.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.